Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2

Conditions

Vulvar Neoplasms 2Vaginal Neoplasms 2Uterine Cervical Neoplasms 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Anus Neoplasms 2Neoplasm Metastasis 1

Interventions

Cyclophosphamide 7pembrolizumab 6fludarabine 6aldesleukin 4fludarabine phosphate 2entinostat 2Trastuzumab 2Radiotherapy 2Psychiatric Rehabilitation 2Nivolumab 2Interleukin-2 2Interleukin-12 Subunit p35 2Early Intervention, Educational 2Adoptive Transfer 2trastuzumab deruxtecan 1tislelizumab 1tipifarnib 1spartalizumab 1rocakinogene sifuplasmid 1oncogene protein E7, Human papillomavirus type 16 1enzalutamide 1durvalumab 1cemiplimab 1bintrafusp alfa protein, human 1atezolizumab 1alovudine 1abiraterone 1Vorinostat 1Vaccines, Synthetic 1VGX-3100 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anus Neoplasms × Adoptive Transfer × Genitourinary × Clear all
NCT05639972 2026-02-27

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Rutgers, The State University of New Jersey

Phase 1/2 Recruiting
15 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT05686226 2026-02-27

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Rutgers, The State University of New Jersey

Phase 2 Recruiting
20 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡